Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Baum, Rp"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 51
Tytuł:
[ -LM4, a PET Radiotracer in the Diagnosis of SST 2 R-Positive Tumors: Preclinical and First Clinical Results.
Autorzy:
Kanellopoulos P; Molecular Radiopharmacy, INRaSTES, NCSR 'Demokritos', GR-15310 Athens, Greece.
Nock BA; Molecular Radiopharmacy, INRaSTES, NCSR 'Demokritos', GR-15310 Athens, Greece.
Greifenstein L; CURANOSTICUM Wiesbaden-Frankfurt, DKD Helios Klinik, D-65191 Wiesbaden, Germany.
Baum RP; CURANOSTICUM Wiesbaden-Frankfurt, DKD Helios Klinik, D-65191 Wiesbaden, Germany.
Roesch F; Department Chemie, Standort TRIGA, Johannes Gutenberg-Universität Mainz, D-55126 Mainz, Germany.
Maina T; Molecular Radiopharmacy, INRaSTES, NCSR 'Demokritos', GR-15310 Athens, Greece.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Nov 23; Vol. 23 (23). Date of Electronic Publication: 2022 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Gallium Radioisotopes*
Neuroendocrine Tumors*
Animals ; Humans ; Mice ; Positron Emission Tomography Computed Tomography/methods ; HEK293 Cells ; Chelating Agents ; Positron-Emission Tomography/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [ .SA.FAPi.
Autorzy:
Greifenstein L; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Kramer CS; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Moon ES; Department of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55128 Mainz, Germany.
Rösch F; Department of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55128 Mainz, Germany.
Klega A; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Landvogt C; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Müller C; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Baum RP; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Pokaż więcej
Źródło:
Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2022 Aug 14; Vol. 15 (8). Date of Electronic Publication: 2022 Aug 14.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Autorzy:
Langbein T; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.; Department of Nuclear Medicine, Technical University of Munich, Klinikum Rechts der Isar, 81675 Munich, Germany.
Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.; BAMF Health, Grand Rapids, MI 49503, USA.
Schuchardt C; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.
Mueller D; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.; Department of Nuclear Medicine, University Hospital Ulm, 89081 Ulm, Germany.
Volk GF; Department of Otorhinolaryngology, Facial-Nerve-Center Jena, Center for Rare Diseases Jena, Jena University Hospital, 07743 Jena, Germany.
Baum RP; Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.; CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Pokaż więcej
Źródło:
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2022 Aug 10; Vol. 12 (8). Date of Electronic Publication: 2022 Aug 10.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.
Autorzy:
Mueller J; Department of Neurology, Vivantes Klinikum Spandau, Neue Bergstrasse 6, D-13585 Berlin, Germany.
Langbein T; Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 München, Germany.
Mishra A; Department of Nuclear Medicine, Curanosticum Wiesbaden, Deutsche Klinik für Diagnostik, Aukammallee 33, D-65191 Wiesbaden, Germany.
Baum RP; Department of Nuclear Medicine, Curanosticum Wiesbaden, Deutsche Klinik für Diagnostik, Aukammallee 33, D-65191 Wiesbaden, Germany.
Pokaż więcej
Źródło:
Toxins [Toxins (Basel)] 2022 Jan 17; Vol. 14 (1). Date of Electronic Publication: 2022 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Botulinum Toxins, Type A/*adverse effects
Parotid Gland/*drug effects
Submandibular Gland/*drug effects
Aged ; Dose-Response Relationship, Drug ; Humans ; Injections ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The ICPO Foundation-on the way toward collaborative growth of theranostics.
Autorzy:
Baum RP; Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany.
Mailman J; NorCal CarciNET Community, San José, CA, USA.
Jaume O; The ICPO Foundation, Humboldtstr. 29, 65189, Wiesbaden, Germany. .
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Jan; Vol. 49 (2), pp. 443-444.
Typ publikacji:
Editorial
MeSH Terms:
Precision Medicine*
Theranostic Nanomedicine*
Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [ Lu]Lu-PSMA-617: a WARMTH multicentre study.
Autorzy:
Ahmadzadehfar H; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. .; Department of Nuclear Medicine, Klinikum Westfalen, Am Knappschaftskrankenhaus 1, 44309, Dortmund, Germany. .
Matern R; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Baum RP; Center for Precision Radiomolecular Oncology, Bad Berka (ZBB), Germany.; Advanced Theranostics Center for Molecular Radiotherapy and Precision Oncology, ICPO Center of Excellence, CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany.
Seifert R; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.; West German Cancer Center, Münster and Essen, Germany.
Kessel K; Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Bögemann M; West German Cancer Center, Münster and Essen, Germany.; Department of Urology, University Hospital Münster, Münster, Germany.
Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Rathke H; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Ilhan H; Department of Nuclear Medicine, LMU, University Hospital Munich, Munich, Germany.
Svirydenka H; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.
Kabasakal L; Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey.
Yordanova A; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.; Department of Radiology, Marienhospital Bonn, Bonn, Germany.
Garcia-Perez FO; Department of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología, Mexico City, Mexico.
Kairemo K; Docrates Cancer Center, Helsinki, Finland.
Maharaj M; Department of Nuclear Medicine, Imaging and Therapy Centre, Durban, KwaZulu-Natal, South Africa.
Paez D; Nuclear Medicine and Diagnostic Imaging Section, Department of Nuclear Sciences and Applications, IAEA, Vienna, Austria.
Virgolini I; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Rahbar K; West German Cancer Center, Münster and Essen, Germany.; Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Nov; Vol. 48 (12), pp. 4067-4076. Date of Electronic Publication: 2021 May 25.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/radiotherapy
Radium*
Dipeptides/adverse effects ; Heterocyclic Compounds, 1-Ring/adverse effects ; Humans ; Male ; Prostate-Specific Antigen ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
Autorzy:
Chantadisai M; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, 99437, Bad Berka, Germany. aueng_.; Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand. aueng_.
Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, 99437, Bad Berka, Germany.
Baum RP; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, 99437, Bad Berka, Germany.; Advanced Theranostics Center for Molecular Radiotherapy and Precision Oncology, ICPO Center of Excellence, CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 May; Vol. 48 (5), pp. 1390-1398. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/radiotherapy
Neuroendocrine Tumors*
Humans ; Prognosis ; Proportional Hazards Models ; Radioisotopes ; Receptors, Peptide
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Autorzy:
Ahmadzadehfar H; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. .; Department of Nuclear Medicine, Klinikum Westfalen, Am Knappschaftskrankenhaus 1, 44309, Dortmund, Germany. .
Rahbar K; Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Baum RP; Center for Radiomolecular Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany.
Seifert R; Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Kessel K; Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Bögemann M; Department of Urology, University Hospital Münster, Muenster, Germany.
Kulkarni HR; Center for Radiomolecular Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany.
Zhang J; Center for Radiomolecular Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany.
Gerke C; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Fimmers R; Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany.
Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Rathke H; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Ilhan H; Department of Nuclear Medicine, LMU, University Hospital Munich, Munich, Germany.
Maffey-Steffan J; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.
Kabasakal L; Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey.
Garcia-Perez FO; Department of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología Mexico City, Mexico City, Mexico.
Kairemo K; Docrates Cancer Center, Helsinki, Finland.
Maharaj M; Department of Nuclear Medicine, Imaging and Therapy Centre, Durban, KwaZulu-Natal, South Africa.
Paez D; Department of Nuclear Sciences and Applications, Nuclear Medicine and Diagnostic Imaging Section, IAEA, Vienna, Austria.
Virgolini I; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Jan; Vol. 48 (1), pp. 113-122. Date of Electronic Publication: 2020 May 08.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Radium*
Aged ; Dipeptides ; Heterocyclic Compounds, 1-Ring ; Humans ; Male ; Prognosis ; Prostate-Specific Antigen ; Radiopharmaceuticals ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment.
Autorzy:
Busse A; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Mochmann LH; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.
Spenke C; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.
Arsenic R; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.; Institute für histologische und zytologische Diagnostik AG Aarau, 5000 Aarau, Switzerland.
Briest F; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.
Jöhrens K; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.; Institute of Pathology, Carl Gustav Carus University Hospital Dresden, 01307 Dresden, Germany.
Lammert H; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.
Sipos B; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, 72076 Tübingen, Germany.; Private Practice of Pathology and Molecular Pathology, 70176 Stuttgart, Germany.
Kühl AA; iPATH Berlin-Immunopathology for Experimental Models, Core Unit of the Charité, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 12203 Berlin, Germany.
Wirtz R; Stratifyer Molecular Oncology GmbH, 50935 Cologne, Germany.
Pavel M; Department of Endocrinology, Universitatsklinikum Erlangen, 91054 Erlangen, Germany.
Hummel M; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.; Central Biobank, Berlin Institute of Health, 10178 Berlin, Germany.
Kaemmerer D; Department of General and Visceral Surgery, Zentralklinik Bad Berka, 99437 Bad Berka, Germany.
Baum RP; CURANOSTICUM Wiesbaden-Frankfurt in der DKD HELIOS Klinik, 65191 Wiesbaden, Germany.
Grabowski P; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 12203 Berlin, Germany.; Institute of Medical Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Nov 19; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 19.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-Dotatate: an analysis of the NETTER-1 study.
Autorzy:
Strosberg J; Gastrointestinal Department/Neuroendocrine Tumor Division, Moffitt Cancer Center, Tampa, FL, USA. .
Kunz PL; Department of Medicine - Med/Oncology, Stanford University Medical Center, Stanford, CA, USA.
Hendifar A; Department of Internal Medicine/Hematology/Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Yao J; Department of Gastrointestinal Medicinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bushnell D; Department of Radiology, The University of Iowa, Iowa City, IA, USA.
Kulke MH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Baum RP; Department of Nuclear Medicine, Zentralklinik Bad Berka, Bad Berka, Germany.
Caplin M; Department of Gastroenterology and Tumour Neuroendocrinology, Royal Free Hospital, London, UK.
Ruszniewski P; Division of Gastroenterology and Pancreatology, Hôpital Beaujon, Clichy, France.
Delpassand E; Department of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, TX, USA.
Hobday T; Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Verslype C; Department of Hepatology, University Hospitals and KU Leuven, Leuven, Belgium.
Benson A; Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Srirajaskanthan R; Department of Gastroenterology and General Internal Medicine, King's College Hospital - NHS Foundation Trust, London, UK.
Pavel M; Division of Hepatology and Gastroenterology, Charite-Universitätsmedizin Berlin, Berlin, Germany.
Mora J; Department of Nuclear Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain.
Berlin J; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Grande E; Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain.
Reed N; Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK.
Seregni E; Department of Nuclear Medicine Therapy and Endocrinology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Paganelli G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Severi S; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Morse M; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Metz DC; GI Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Ansquer C; Nuclear Medicine Department, Hôtel Dieu, University Hospital, Nantes, France.
Courbon F; Medical Imaging, Oncology University Institut Claudius Regaud, Toulouse, France.
Al-Nahhas A; Division of Imaging and Interventional Radiology, Imperial College London, London, UK.
Baudin E; Department of Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France.
Giammarile F; Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
Taïeb D; Department of Nuclear Medicine, Hôpital de la Timone, Marseille, France.
Mittra E; Department of Nuclear Medicine, Oregon Health & Science University, Portland, OR, USA.
Wolin E; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
O'Dorisio TM; Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA.
Lebtahi R; Department of Nuclear Medicine, Royal Free Hospital, London, UK.
Deroose CM; Nuclear Medicine Department, University Hospitals and KU Leuven, Leuven, Belgium.
Grana CM; Division of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy.
Bodei L; Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Öberg K; Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.
Polack BD; Department of Medical Information, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
He B; Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Mariani MF; Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Gericke G; Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Santoro P; Department of Clinical Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Erion JL; Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Ravasi L; Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland.
Krenning E; Department of Nuclear Medicine, Cyclotron Rotterdam BV, Erasmus University Medical Center, Rotterdam, Netherlands.
Pokaż więcej
Corporate Authors:
NETTER-1 study group
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Sep; Vol. 47 (10), pp. 2372-2382. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Liver Neoplasms*/radiotherapy
Neuroendocrine Tumors*/radiotherapy
Organometallic Compounds*/therapeutic use
Alkaline Phosphatase ; Humans ; Octreotide/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Autorzy:
Bodei L; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY, 10065, USA. .; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK. .
Kidd MS; Wren Laboratories, Branford, CT, USA.
Singh A; Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
van der Zwan WA; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Severi S; Nuclear Medicine and Radiometabolic Units, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Drozdov IA; Wren Laboratories, Branford, CT, USA.
Malczewska A; Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, Poland.
Baum RP; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Kwekkeboom DJ; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Paganelli G; Nuclear Medicine and Radiometabolic Units, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Krenning EP; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.; Cyclotron Rotterdam BV, Erasmus Medical Center, Rotterdam, The Netherlands.
Modlin IM; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Yale School of Medicine, New Haven, CT, USA.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Apr; Vol. 47 (4), pp. 895-906. Date of Electronic Publication: 2019 Dec 14.
Typ publikacji:
Journal Article
MeSH Terms:
Neuroendocrine Tumors*/radiotherapy
Pancreatic Neoplasms*
Biomarkers, Tumor ; Humans ; Italy ; Netherlands
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preclinical investigations and first-in-human application of Tb-PSMA-617 for PET/CT imaging of prostate cancer.
Autorzy:
Müller C; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland. .
Singh A; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany.; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands.
Umbricht CA; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany.
Johnston K; CERN, Geneva, Switzerland.
Benešová M; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Senftleben S; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany.
Müller D; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany.
Vermeulen C; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Köster U; Institut Laue-Langevin, Grenoble, France.
van der Meulen NP; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland.
Baum RP; Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437, Bad Berka, Germany.
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2019 Jul 25; Vol. 9 (1), pp. 68. Date of Electronic Publication: 2019 Jul 25.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Instant kit preparation of Ga]Ga-DATA-TOC.
Autorzy:
Sinnes JP; Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany.
Nagel J; Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany.
Waldron BP; Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany.
Maina T; Molecular Radiopharmacy, INRASTES NCSR 'Demokritos', Athens, Greece.
Nock BA; Molecular Radiopharmacy, INRASTES NCSR 'Demokritos', Athens, Greece.
Bergmann RK; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Ullrich M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Pietzsch J; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany.
Bachmann M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Technische Universität Dresden, Universitätsklinikum 'Carl Gustav Carus', UniversitätsKrebsCentrum (UCC), Tumorimmunology, Dresden, Germany.; National Center for Tumor Diseases (NCT), Technische Universität Dresden, Dresden, Germany.
Baum RP; Zentralklinik Bad Berka GmbH, Clinic for Molecular Radiotherapy, Bad Berka, Germany.
Rösch F; Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany. .
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2019 May 23; Vol. 9 (1), pp. 48. Date of Electronic Publication: 2019 May 23.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PRRT genomic signature in blood for prediction of Lu-octreotate efficacy.
Autorzy:
Bodei L; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY, 10065, USA. .; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK. .
Kidd MS; Wren Laboratories, Branford, CT, USA.
Singh A; Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
van der Zwan WA; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Severi S; Nuclear Medicine and Radiometabolic Units, Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Drozdov IA; Wren Laboratories, Branford, CT, USA.
Cwikla J; University of Warmia and Mazury, Olsztyn, Poland.
Baum RP; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Kwekkeboom DJ; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Paganelli G; Nuclear Medicine and Radiometabolic Units, Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Krenning EP; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Cyclotron Rotterdam BV, Erasmus University Medical Center, Rotterdam, The Netherlands.
Modlin IM; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka, 54 Portland Place, London, W1B1DY, UK.; Yale School of Medicine, New Haven, USA.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2018 Jul; Vol. 45 (7), pp. 1155-1169. Date of Electronic Publication: 2018 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Genomics*
Positron Emission Tomography Computed Tomography*
Neuroendocrine Tumors/*drug therapy
Octreotide/*analogs & derivatives
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/diagnostic imaging ; Octreotide/therapeutic use ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.
Autorzy:
Binzel K; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Adelaja A; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Wright CL; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Scharre D; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Zhang J; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Knopp MV; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Teoh EJ; Departments of Radiology and Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Bottomley D; The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Scarsbrook A; The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Payne H; University College London, London, UK.
Afaq A; University College London, London, UK.
Bomanji J; University College London, London, UK.
van As N; The Royal Marsden NHS Foundation Trust, London, UK.
Chua S; The Royal Marsden NHS Foundation Trust, London, UK.
Hoskin P; Mount Vernon Cancer Centre, London, UK.
Chambers A; Mount Vernon Cancer Centre, London, UK.
Cook GJ; King's College London, London, UK.
Warbey VS; King's College London, London, UK.
Chau A; Blue Earth Diagnostics, Oxford, UK.
Ward P; Blue Earth Diagnostics, Oxford, UK.
Miller MP; Blue Earth Diagnostics, Oxford, UK.
Stevens DJ; Blue Earth Diagnostics, Oxford, UK.
Wilson L; Blue Earth Diagnostics, Oxford, UK.
Gleeson FV; Departments of Radiology and Nuclear Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Scheidhauer K; TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany.
Seidl C; TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany.
Autenrieth M; TU München, Klinikum rechts der Isar, Urologie, München, Germany.
Bruchertseifer F; JRC, Institute for Transuranium, Karlsruhe, Germany.
Apostolidis C; JRC, Institute for Transuranium, Karlsruhe, Germany.
Kurtz F; TU München, Klinikum rechts der Isar, Urologie, München, Germany.
Horn T; TU München, Klinikum rechts der Isar, Urologie, München, Germany.
Pfob C; TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany.
Schwaiger M; TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany.
Gschwend J; TU München, Klinikum rechts der Isar, Urologie, München, Germany.
D'Alessandria C; TU München, Klinikum rechts der Isar, Nuklearmedizin, München, Germany.
Morgenstern A; JRC, Institute for Transuranium, Karlsruhe, Germany.
Uprimny C; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Kroiss A; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Decristoforo C; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
von Guggenberg E; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Nilica B; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Horninger W; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Virgolini I; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 32, 6020, Innsbruck, Austria.
Rasul S; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Poetsch N; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Woehrer A; Clinical Institute of Neurology, Medical University of Vienna, Vienna, Austria.
Preusser M; Clinical University of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Mitterhauser M; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Wadsak W; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.; CBmed GmbH, Center for Biomarker Research in Medicine, Graz, Austria.
Widhalm G; Clinical University of Neuro-surgery, Medical University of Vienna, Vienna, Austria.
Mischkulnig M; Clinical University of Neuro-surgery, Medical University of Vienna, Vienna, Austria.
Hacker M; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Traub-Weidinger T; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Wright CL; Wright Center of Innovation, The Ohio State University, Columbus, OH, USA.
Binzel K; Wright Center of Innovation, The Ohio State University, Columbus, OH, USA.
Wuthrick EJ; Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Miller ED; Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Maniawski P; Clinical Science, Philips Healthcare, Cleveland, OH, USA.
Zhang J; Wright Center of Innovation, The Ohio State University, Columbus, OH, USA.
Knopp MV; Wright Center of Innovation, The Ohio State University, Columbus, OH, USA.
Rep S; Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Hocevar M; Department of Oncological Surgery, Oncology Institute Ljubljana, Ljubljana, Slovenia.
Vaupotic J; Jozef Stefan Institute Ljubljana, Ljubljana, Slovenia.
Zdesar U; Institute of Occupational Safety Ljubljana, Ljubljana, Slovenia.
Zaletel K; Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Lezaic L; Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Mairinger S; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Filip T; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Sauberer M; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Flunkert S; Neuropharmacology, QPS Austria GmbH, Grambach, Austria.
Wanek T; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Stanek J; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Okamura N; Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Langer O; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Kuntner C; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Fornito MC; Nuclear Medicine Department PET/TC center Arnas Garibaldi Catania, Catania, Italy.
Balzano R; Nuclear Medicine Department PET/TC center Arnas Garibaldi Catania, Catania, Italy.
Di Martino V; Nuclear Medicine Department PET/TC center Arnas Garibaldi Catania, Catania, Italy.
Cacciaguerra S; Pediatric Surgery Department Arnas Garibaldi Catania, Catania, Italy.
Russo G; H. Pharmacy Department Arnas Garibaldi Catania, Catania, Italy.
Seifert D; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Kleinova M; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Cepa A; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Ralis J; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Hanc P; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Lebeda O; Nuclear Physics Institute of the CAS, Rez, Czech Republic.
Mosa M; Charles university Faculty of Science Prague, Prague, Czech Republic.
Vandenberghe S; MEDISIP research group, Ghent University, Ghent, Belgium.
Mikhaylova E; UC Davis, Davis, CA, USA.
Borys D; Silesian University of Technology Gliwice, Gliwice, Poland.
Viswanath V; PET instrumentation group, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Stockhoff M; MEDISIP research group, Ghent University, Ghent, Belgium.
Efthimiou N; MEDISIP research group, Ghent University, Ghent, Belgium.
Caribe P; MEDISIP research group, Ghent University, Ghent, Belgium.
Van Holen R; MEDISIP research group, Ghent University, Ghent, Belgium.
Karp JS; PET instrumentation group, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Binzel K; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Zhang J; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Wright CL; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Maniawski P; Philips Healthcare, Cleveland, Ohio, USA.
Knopp MV; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Haller PM; 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
Farhan C; Department of Nuclear Medicine with PET-Center, Wilhelminenhospital, Vienna, Austria.
Piackova E; 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
Jäger B; 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Knoll P; Department of Nuclear Medicine with PET-Center, Wilhelminenhospital, Vienna, Austria.
Kiss A; Department of Biomedical Research, Medical University of Vienna, Vienna, Austria.
Podesser BK; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.; Department of Biomedical Research, Medical University of Vienna, Vienna, Austria.
Wojta J; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
Huber K; 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.; Sigmund Freud University, Medical Faculty, Vienna, Austria.
Mirzaei S; Department of Nuclear Medicine with PET-Center, Wilhelminenhospital, Vienna, Austria.
Traxl A; Center for Health & Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Komposch K; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Glitzner E; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Wanek T; Center for Health & Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Mairinger S; Center for Health & Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Sibilia M; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Langer O; Center for Health & Bioresources, Biomedical Systems, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Fornito MC; Nuclear Medicine Department PET/TC Center ARNAS Garibaldi, Catania, Italy.
Russello M; Liver Unit ARNAS Garibaldi, Catania, Italy.
Russo G; H.Pharmacy Department ARNAS Garibaldi, Catania, Italy.
Balzano R; Nuclear Medicine Department PET/TC Center ARNAS Garibaldi, Catania, Italy.
Sorko S; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Gallowitsch HJ; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Kohlfuerst S; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Matschnig S; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Rieser M; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Sorschag M; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Lind P; Department of Nuclear Medicine and Endocrinology, PET/CT Center, Klinikum Klagenfurt, Klagenfurt, Austria.
Ležaič L; Departments of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Rep S; Departments of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Žibert J; Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia.
Frelih N; Departments of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Šuštar S; Departments of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Binzel K; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Adelaja A; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Wright CL; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Scharre D; Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Zhang J; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Knopp MV; Wright Center of Innovation in Biomedical Imaging, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Baum RP; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Langbein T; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Singh A; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Shahinfar M; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Schuchardt C; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Volk GF; Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany.
Kulkarni HR; Theranostics Center for Molecular Radiotherapy and Molecular ImagZentralklinik Bad Berka, Bad Berka, Germany.
Fornito MC; Nuclear Medicine Department Arnas Garibaldi, Catania, Italy.
Cacciaguerra S; Pediatric Surgery Arnas Garibaldi, Catania, Italy.
Balzano R; Nuclear Medicine Department Arnas Garibaldi, Catania, Italy.
Di Martino GV; Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany.
Russo G; Pharmacy H. Department Arnas Garibaldi, Catania, Italy.
Thomson WH; Physics and Nuclear Medicine, City Hospital, Birmingham, UK.
Kudlacek M; Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria.
Karik M; Department of Viceral and General Surgery, Wilhelminenspital, Vienna, Austria.
Farhan C; Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria.
Rieger H; Institute of Pathology and Microbiology, Wilhelminenspital, Vienna, Austria.
Pokieser W; Institute of Pathology and Microbiology, Wilhelminenspital, Vienna, Austria.
Glaser K; Department of Viceral and General Surgery, Wilhelminenspital, Vienna, Austria.
Mirzaei S; Institute of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria.
Petz V; Schilddruesenpraxis Josefstadt, Vienna, Austria.
Tugendsam C; Schilddruesenpraxis Josefstadt, Vienna, Austria.
Buchinger W; Schilddrueseninstitut Gleisdorf, Gleisdorf, Austria.
Schmoll-Hauer B; Schilddruesenpraxis Josefstadt, Vienna, Austria.; Department of Nuclear Medicine, Krankenanstalt Rudolfstiftung, Vienna, Austria.
Schenk IP; Schilddruesenpraxis Josefstadt, Vienna, Austria.; Department of Nuclear Medicine, Sozialmedizinisches Zentrum Hietzing, Vienna, Austria.
Rudolph K; Schilddruesenpraxis Josefstadt, Vienna, Austria.
Krebs M; Schilddruesenpraxis Josefstadt, Vienna, Austria.; Clinical Division of Endocrinology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Zettinig G; Schilddruesenpraxis Josefstadt, Vienna, Austria.
Zoufal V; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Wanek T; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Krohn M; Department of Neuro-/Pathology, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
Mairinger S; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Stanek J; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Sauberer M; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Filip T; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Pahnke J; Department of Neuro-/Pathology, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
Langer O; Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Weitzer F; Meduni Graz, Univ. Klinik für Radiologie, Abteilung für Nuklearmedizin, Graz, Austria.
Pernthaler B; Meduni Graz, Univ. Klinik für Radiologie, Abteilung für Nuklearmedizin, Graz, Austria.
Salamon S; Meduni Graz, Univ. Klinik für Radiologie, Abteilung für Nuklearmedizin, Graz, Austria.
Aigner R; Meduni Graz, Univ. Klinik für Radiologie, Abteilung für Nuklearmedizin, Graz, Austria.
Koranda P; Department of Nuclear Medicine, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
Henzlová L; Department of Nuclear Medicine, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
Kamínek M; Department of Nuclear Medicine, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
Váchalová M; Department of Vascular and Transplantation Surgery, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
Bachleda P; Department of Vascular and Transplantation Surgery, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
Summer D; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.
Garousi J; Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185, Uppsala, Sweden.
Oroujeni M; Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185, Uppsala, Sweden.
Mitran B; Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, SE-751 83, Uppsala, Sweden.
Andersson KG; Division of Protein Technology, KTH Royal Institute of Technology, SE-10691, Stockholm, Sweden.
Vorobyeva A; Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185, Uppsala, Sweden.
Löfblom JN; Division of Protein Technology, KTH Royal Institute of Technology, SE-10691, Stockholm, Sweden.
Orlova A; Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, SE-751 83, Uppsala, Sweden.
Tolmachev V; Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185, Uppsala, Sweden.
Decristoforo C; Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria.
Kaeopookum P; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.; Research and Development Division, Thailand Institute of Nuclear Technology, Nakhonnayok, Thailand.
Summer D; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Orasch T; Division of Molecular Biology, Biocenter, Medical University Innsbruck, Innsbruck, Austria.
Lechner B; Division of Molecular Biology, Biocenter, Medical University Innsbruck, Innsbruck, Austria.
Petrik M; Faculty of Medicine and Dentistry, Institute of Molecular and Translation Medicine, Palacky University, Olomouc, Czech Republic.
Novy Z; Faculty of Medicine and Dentistry, Institute of Molecular and Translation Medicine, Palacky University, Olomouc, Czech Republic.
Rangger C; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Haas H; Division of Molecular Biology, Biocenter, Medical University Innsbruck, Innsbruck, Austria.
Decristoforo C; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2018 Jan 23; Vol. 8 (Suppl 1), pp. 5. Date of Electronic Publication: 2018 Jan 23.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.
Autorzy:
Pfannkuchen N; Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany. .
Meckel M; Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany. .
Bergmann R; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany. .
Bachmann M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany. .; University Cancer Center (UCC) Carl Gustav Carus, Tumorimmunology, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany. .
Bal C; Department of Nuclear Medicine & PET, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. .
Sathekge M; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Private Bag X169, Pretoria 0001, South Africa. .
Mohnike W; Diagnostisch Therapeutisches Zentrum, DTZ am Frankfurter Tor, Kadiner Straße 23, 10243 Berlin, Germany. .
Baum RP; Department of Nuclear Medicine, Center for PET/CT, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99438 Bad Berka, Germany. richard.baum@zentralklinik.de.
Rösch F; Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany. .
Pokaż więcej
Źródło:
Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2017 May 18; Vol. 10 (2). Date of Electronic Publication: 2017 May 18.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.
Autorzy:
Chan HS; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. .
Konijnenberg MW; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
de Blois E; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Koelewijn S; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Baum RP; Department of Nuclear Medicine/Center for PET/CT, Zentralklinik, Bad Berka, Germany.
Morgenstern A; Institute for Transuranium Elements (ITU), Joint Research Centre, European Commission, Karlsruhe, Germany.
Bruchertseifer F; Institute for Transuranium Elements (ITU), Joint Research Centre, European Commission, Karlsruhe, Germany.
Breeman WA; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
de Jong M; Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.; Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
EJNMMI research [EJNMMI Res] 2016 Dec; Vol. 6 (1), pp. 6. Date of Electronic Publication: 2016 Jan 20.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
Autorzy:
Kletting P; Department of Nuclear Medicine, Ulm University, Ulm, Germany.
Schuchardt C; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany.
Kulkarni HR; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany.
Shahinfar M; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany.
Singh A; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany.
Glatting G; Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Baum RP; THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany.
Beer AJ; Department of Nuclear Medicine, Ulm University, Ulm, Germany.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0162303. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Typ publikacji:
Journal Article
MeSH Terms:
Antigens, Surface/*therapeutic use
Glutamate Carboxypeptidase II/*therapeutic use
Lutetium/*therapeutic use
Prostatic Neoplasms/*radiotherapy
Radioisotopes/*therapeutic use
Aged ; Antigens, Surface/chemistry ; Computer Simulation ; Dose-Response Relationship, Drug ; Drug Delivery Systems ; Glutamate Carboxypeptidase II/chemistry ; Glutamate Carboxypeptidase II/pharmacokinetics ; Humans ; Kidney/metabolism ; Ligands ; Lutetium/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; Peptides/pharmacokinetics ; Peptides/therapeutic use ; Prostatic Neoplasms/metabolism ; Radioisotopes/pharmacokinetics ; Retrospective Studies ; Salivary Glands/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Autorzy:
Maina T; Molecular Radiopharmacy, INRASTES, NCSR 'Demokritos', Ag. Paraskevi Attikis, 15310, Athens, Greece. maina_.
Bergsma H; Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Kulkarni HR; Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany.
Mueller D; Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany.
Charalambidis D; Molecular Radiopharmacy, INRASTES, NCSR 'Demokritos', Ag. Paraskevi Attikis, 15310, Athens, Greece.
Krenning EP; Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Nock BA; Molecular Radiopharmacy, INRASTES, NCSR 'Demokritos', Ag. Paraskevi Attikis, 15310, Athens, Greece.
de Jong M; Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.; Department of Radiology, Erasmus MC, Rotterdam, The Netherlands.
Baum RP; Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2016 May; Vol. 43 (5), pp. 964-973. Date of Electronic Publication: 2015 Dec 02.
Typ publikacji:
Journal Article
MeSH Terms:
Positron Emission Tomography Computed Tomography*
Bombesin/*analogs & derivatives
Breast Neoplasms/*diagnostic imaging
Coordination Complexes/*pharmacokinetics
Oligopeptides/*pharmacokinetics
Prostatic Neoplasms/*diagnostic imaging
Radiopharmaceuticals/*pharmacokinetics
Receptors, Bombesin/*antagonists & inhibitors
Adult ; Aged ; Animals ; Cell Line, Tumor ; Coordination Complexes/chemistry ; Female ; Gallium Radioisotopes ; Humans ; Male ; Mice ; Mice, SCID ; Middle Aged ; Oligopeptides/chemistry ; Radiopharmaceuticals/administration & dosage ; Radiopharmaceuticals/adverse effects ; Receptors, Bombesin/metabolism ; Tissue Distribution
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Autorzy:
Bodei L; Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy.; LuGenIum Consortium, Milan, Rotterdam, Bad Berka, London, Italy, Netherlands, Germany, UK.
Kidd M; Wren Laboratories, Branford, CT, USA.
Modlin IM; LuGenIum Consortium, Milan, Rotterdam, Bad Berka, London, Italy, Netherlands, Germany, UK. .; Yale School of Medicine, 310 Cedar St, New Haven, New Haven, 06510, CT, USA. .
Severi S; Nuclear Medicine and Radiometabolic Units, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Drozdov I; Bering Limited, London, UK.
Nicolini S; Nuclear Medicine and Radiometabolic Units, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Kwekkeboom DJ; LuGenIum Consortium, Milan, Rotterdam, Bad Berka, London, Italy, Netherlands, Germany, UK.; Nuclear Medicine Department, Erasmus Medical Center, Rotterdam, The Netherlands.
Krenning EP; LuGenIum Consortium, Milan, Rotterdam, Bad Berka, London, Italy, Netherlands, Germany, UK.; Nuclear Medicine Department, Erasmus Medical Center, Rotterdam, The Netherlands.
Baum RP; LuGenIum Consortium, Milan, Rotterdam, Bad Berka, London, Italy, Netherlands, Germany, UK.; Theranostics Center for Molecular Radiotherapy and Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Paganelli G; Nuclear Medicine and Radiometabolic Units, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Pokaż więcej
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2016 May; Vol. 43 (5), pp. 839-851. Date of Electronic Publication: 2015 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers, Tumor/*blood
Neuroendocrine Tumors/*blood
Octreotide/*analogs & derivatives
RNA, Messenger/*blood
Radiopharmaceuticals/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Chromogranin A/blood ; Cluster Analysis ; Female ; Gene Regulatory Networks ; Humans ; Male ; Metabolome ; Middle Aged ; Neuroendocrine Tumors/radiotherapy ; Octreotide/therapeutic use ; RNA, Messenger/genetics ; Receptors, Peptide/metabolism ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 51

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies